- 专利标题： Multispecific antibodies against IL-5 and IL-4R
-
申请号： US16966237申请日： 2019-02-15
-
公开(公告)号： US12030949B2公开(公告)日： 2024-07-09
- 发明人: Christophe Blanchetot , Marie Godar , Bart Lambrecht
- 申请人： argenx BV
- 申请人地址： BE Ghent
- 专利权人： argenx BV
- 当前专利权人： argenx BV
- 当前专利权人地址： BE Ghent
- 代理机构： Dechert LLP
- 代理商 Andrew T. Wilkins; Kayla L. Metzger
- 优先权： GB 02487 2018.02.15
- 国际申请： PCT/EP2019/053890 2019.02.15
- 国际公布： WO2019/158728A 2019.08.22
- 进入国家日期： 2020-07-30
- 主分类号： C07K16/18
- IPC分类号： C07K16/18 ; C07K16/24 ; C07K16/28
摘要：
The present invention relates to combination therapies and to their use in the treatment of chronic airway disease, particularly use in the treatment of asthma. The combination therapies comprise (i) an antagonist of IL-5:IL-5R and (ii) an antagonist of IL-4:IL-4R and/or an antagonist of IL-13:IL-13R. The present invention also provides bispecific antibodies comprising an antigen binding domain that binds to IL-4Rα and an antigen binding domain that binds to IL-5. The bispecific antibodies may be used for the treatment of chronic airway disease, particularly asthma.
公开/授权文献
- US2200607A Method for making pure hydrogen 公开/授权日：1940-05-14
信息查询
